Abstract: |
(from the chapter) Cognitive dysfunction associated with cancer and cancer treatment has been increasingly recognized and reported by patients. In breast cancer survivors, the most widely investigated cancer cohort, cognitive dysfunction is experienced in 17%-75% of women, at time points between six months to 20 years after completion of treatment.' A majority of longitudinal studies utilizing objective cognitive assessments have found significant changes from pre- to post-treatment.' Interestingly, in two studies, cognitive dysfunction was found prior to adjuvant therapy in 20%-30% of patients diagnosed with breast cancer. Due to this research and the increasing awareness of potential cognitive difficulties by patients, objective measures of cognitive functioning that can detect subtle declines in function are necessary. This chapter focuses on the relative utility of brief and more extensive objective cognitive measures to detect cancer-associated cognitive dysfunction (CACD) in survivors. We will first discuss brief cognitive screening measures and their utility in detecting dysfunction, and then move on to more comprehensive neuropsychological assessment measures and their use in cancer survivors. The sensitivity and specificity of these measures in the detection of CACD, as well as their effect on patient outcomes, will be discussed. (PsycINFO Database Record (c) 2015 APA, all rights reserved). |